Biotech Premarket Movers: Spectrum, BioCryst, Curis

Biotech Premarket Movers: Spectrum, BioCryst, Curis


Shares of Spectrum Pharmaceuticals were down 12% to $5.50 in premarket trading on Thursday. The Henderson, Nev.-based company, which focuses on hematology and oncology, after the market close on Wednesday reported a fourth-quarter net loss of $17.4 million, or 22 cents per basic and diluted share, compared with a net loss of $4.2 million, or 6 cents per basic and diluted share in the year-ago period.



from Biotech News